These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 10833901)
1. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study. Sasor A; Wagrowska-Danilewicz M; Danilewicz M Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901 [TBL] [Abstract][Full Text] [Related]
2. Correlation between histological type and immunohistochemical profile of prostate cancer and gleason scale gradation. Iemelynova AA; Grygorenko VM; Cheremuha SV; Romanenko AM Exp Oncol; 2009 Dec; 31(4):246-9. PubMed ID: 20010526 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Tamboli P; Amin MB; Xu HJ; Linden MD Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma. Petrescu A; Mârzan L; Codreanu O; Niculescu L Rom J Morphol Embryol; 2006; 47(2):143-6. PubMed ID: 17106522 [TBL] [Abstract][Full Text] [Related]
5. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone. Leav I; McNeal JE; Ho SM; Jiang Z Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556 [TBL] [Abstract][Full Text] [Related]
6. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134 [TBL] [Abstract][Full Text] [Related]
7. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases. Zhao J; Epstein JI Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862 [TBL] [Abstract][Full Text] [Related]
8. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106 [TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma. Tamboli P; Amin MB; Schultz DS; Linden MD; Kubus J Mod Pathol; 1996 Oct; 9(10):1015-9. PubMed ID: 8902840 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of cell-cycle associated markers on paraffin embedded and formalin fixed needle biopsies of prostate cancer: correlation of p120 protein expression with AgNOR, PCNA/cyclin, Ki-67/MIB1 proliferation-scores and Gleason gradings. Botticelli AR; Casali AM; Botticelli L; Zaffe D Eur J Histochem; 1998; 42(1):41-8. PubMed ID: 9615190 [TBL] [Abstract][Full Text] [Related]
11. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167 [TBL] [Abstract][Full Text] [Related]
12. [P53 expression and its clinical significance in prostatic carcinoma]. Jiang T; Jiang H; Song XS; Li XC; Li QL Zhonghua Nan Ke Xue; 2005 Jun; 11(6):448-51, 454. PubMed ID: 15999492 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Petraki CD; Gregorakis AK; Papanastasiou PA; Karavana VN; Luo LY; Diamandis EP Prostate Cancer Prostatic Dis; 2003; 6(3):223-7. PubMed ID: 12970725 [TBL] [Abstract][Full Text] [Related]
14. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer. Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240 [TBL] [Abstract][Full Text] [Related]
15. Reduction of QM protein expression correlates with tumor grade in prostatic adenocarcinoma. Altinok G; Powell IJ; Che M; Hormont K; Sarkar FH; Sakr WA; Grignon D; Liao DJ Prostate Cancer Prostatic Dis; 2006; 9(1):77-82. PubMed ID: 16331298 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix. Cina SJ; Richardson MS; Austin RM; Kurman RJ Mod Pathol; 1997 Mar; 10(3):176-80. PubMed ID: 9071723 [TBL] [Abstract][Full Text] [Related]
17. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Mirtti T; Alanen K; Kallajoki M; Rinne A; Söderström KO Prostate; 2003 Mar; 54(4):290-8. PubMed ID: 12539227 [TBL] [Abstract][Full Text] [Related]
18. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Shibata MA; Ward JM; Devor DE; Liu ML; Green JE Cancer Res; 1996 Nov; 56(21):4894-903. PubMed ID: 8895741 [TBL] [Abstract][Full Text] [Related]